A comparative clinical study of hypolipidemic efficacy of Amla (Emblica officinalis) with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor simvastatin

Indian Journal of Pharmacology

Volumn 44, Issue 2, 2012, Pages 238-242

  Gopa, Biswas ^a   Bhatt, Jagatkumar ^a   Hemavathi, Kovur G ^a  

^a Baroda Medical College   (India)

Author keywords

Amla; clinical study; hyperlipidemia; lipid profile; simvastatin

Indexed keywords

CHOLESTEROL; EMBLICA OFFICINALIS EXTRACT; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DRUG CAPSULE; DRUG EFFICACY; EMBLICA OFFICINALIS; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84858966628     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.93857     Document Type: Article

References (30)

1. Assman G, Schulte H. Relation of high density cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (The PROCAM experience). Am J Cardiol 1992;70:733-7.
2. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975;1:16-9.
3. Davey-Smith G, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors and mortality. The White Hall Study. Circulation 1990;82:1925-31.
4. Mukherjee S. Therapeutic management of hyperlipidemia - Rationale and outcome. Assoc Physicians India 2002:315-30.
5. Casdorph HR. The single dose method of administering cholestyramine. Angiology 1975;26:671-82.
6. Huninghake DB, Probstfeild JL, Crow LO, Isaacson SO. Effect of colestipol and clofibrate on plasma lipid and lipoprotein in type IIa hyperlipoproteinemia. Metabolism 1981;30:605-9. (Pubitemid 11116924)
7. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (cholestogel): A new side effect. Arch Intern Med 1999;159:1893-900.
8. Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989;111:253-5.
9. Rubin HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemifibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High Density Lipoprotein Cholesterols Intervention Trial Study Group. N Engl J Med 1999;341:410-8. (Pubitemid 29362514)
10. Alexandridis G, Pappas GA, Elisaf MS. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. Am J Med 2000;109:261-2.
11. Downis JR, Clearfield M, Weis S, Whitney E, Shaprio DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/Tex CAPS. JAMA 1998;279:1615-22.
12. Nakad A, Bataille L, Hamior V, Sempoux C, Horsmans V. Atorvastatin induced acute hepatitis with absence of cross toxicity with simvastatin. Lancet 1999;353:1763-4. (Pubitemid 29240380)
13. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin, gemfibrozil combination therapy. Am J Cardiol 1999;83:1146. (Pubitemid 29162811)
14. Rani G, Bala S, Grover I S. Antimutagenic studies of diethyl ether extract and tannin fractions of Emblica myroblan (Emblica officinalis) in Ames assay. J Plant Sci Res 1994;10:1-4.
15. Arora BB. 8.7 mg of vitamin C from amla is equivalent to 100 mg of vitamin C from synthetic sources. Dev Unani Drugs Herb Sour 1985. P. 234.
16. Gulati R, Agrawal S, Agarwal SS. Hepatoprotective studies on phyllanthus emblica and querectin. Indian J Exp Biol 1995;33:261-8.
17. Kumar KC, Muller K. Medicinal plants from Nepal II. Evaluation as inhibitors of lipid peroxidation in biological membranes. J Ethnopharmacol 1999;64:135-9.
18. Biswas S, Talukdar G, Sharma A. Protection against cytotoxic effects of arsenic by dietary supplementation with crude extract of Emblica officinalis fruit. Phytother Res 1999;13:513-6. (Pubitemid 29445771)
19. Mathur R, Sharma A, Dixit VP, Varma M. Hypolipidemic effect of fruit juice of Emblica officinalis in cholesterol - fed rabbits. J Ethnopharmacol 1996;50:61-8. (Pubitemid 26064144)
20. Jacob A, Pandey M, Kapoor S, Saroja R. Effect of the Indian gooseberry (amla) on serum cholesterol level in men aged 35-55 years. Eur J Clin Nutr 1988;42:939-44. (Pubitemid 19003789)
21. Alloin CC, Poom LS, Chan CS. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470.
22. Bucolo G, David H. Quantitative determination of serum triglyceride by the use of enzymes. Clin Chem 1973;19:476.
23. Stamler M, Wenworth D, Neaton JD. For the MRFIT. Is the relationship between serum cholesterol and risk of premature death from coronary artery disease continuous and graded? Finding in trial. (MRFIT). JAMA 1986;256:2823-8.
24. Kuirtrervich PO Jr. The antiartherogenic role of high density lipoprotein cholesterol. Am J Cardiol 1998;82:13Q-21.
25. Scandinavian Simvastatin Survival Study group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The SSSS (4S). Lancet 1994;344:1383-9.
26. Lipid Research Clinic Program: The lipid research clinic. Coronary Primary Prevention Trial Results II. The relationship of reduction in incidences of coronary artery disease to cholesterol lowering. JAMA 1984;251:365-74.
27. Bhattacharya A, Chatterjee A, Ghoshal S, Bhattacharya SK. Antioxidant activity of active tannoid principle of Emblica offinalis (Amla). Indian J Exp Biol 2000; 37:676-80. (Pubitemid 29309692)
28. Anila L, Vijyalaxmi NR. Beneficial effects of flavanoids from Seasamum indicum, Emblica offinalis and Momordica charantia. Phytother Res 2000;14:592-5.
29. Anila L, Vijyalaxmi NR. Flavanoids from Emblica offinalis and Magnifera indica: Effectiveness for dyslipidemia. J Ethnopharmacol 2002;79:81-7. (Pubitemid 34017244)
30. Bhatia J, Tabassum F, Sharma AK, Bharati S, Golechha M, Joshi S, et al. Emblica officinalis exerts antihypertensive effect in a rat model of DOCA-salt-induced hypertension: Role of (p) eNOS, NO and oxidative stress. Cardiovasc Toxicol 2011;11:272-9.